Search Results - "Zarotsky, V."

Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men by Zarotsky, V., Huang, M.‐Y., Carman, W., Morgentaler, A., Singhal, P. K., Coffin, D., Jones, T. H.

“…Summary The objective of this review was to summarize the literature on the risk factors, comorbidities, and consequences of male hypogonadism, which is…”
Get full text

Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data by Seftel, A D, de la Rosette, J, Birt, J, Porter, V, Zarotsky, V, Viktrup, L

“…Assess and categorise the available prevalence data on coexistent LUTS and ED in the general population and among individuals consulting a healthcare provider…”
Get more information

Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims by Copher, R., Buzinec, P., Zarotsky, V., Kazis, L., Iqbal, S.U., Macarios, D.

“…Abstract Objective: This study explored physicians’ perceptions of patient adherence to medications compared with patient adherence derived by…”
Get full text

Development of an algorithm that differentiates among risk factors, comorbidities, and consequences of disease in peer-reviewed publications by Carman, W, Zarotsky, V

Get full text

Building a bridge: ICD-9-CM to ICD-10-CM mapping challenges and solutions by Seare, J, Yang, J, Yu, S, Zarotsky, V

Get full text

review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity by Cantrell, R.A, Alatorre, C.I, Davis, E.J, Zarotsky, V, Le Nestour, E, Carter, G. Cuyún, Goetz, I, Paczkowski, R, Sierra-Johnson, J

“…The response to treatment for type 2 diabetes typically varies among individuals within a study population. This variation is known as heterogeneity of…”
Get full text

The Prevalence, Incidence, And Treatment Rates Of Hypogonadism In Men Across Geographies: A Systematic Literature Review by Huang, M.Y, Parker, G, Zarotsky, V, Carman, W, Morgentaler, A, Jones, H, Singhal, P

Get full text

Care pathway and cost for absssi subjects with antibiotic treatment in the united states: An analysis of a real world database by Fan, W, Mao, J, Iorga, S, Zarotsky, V, LaPensee, K.T, Becker, L

Get full text

Please pass the new template: developing non-interventional study report writing templates aligned with guidelines by Oberthur Johnson, L, Zarotsky, V, Spannheimer, A, Gulyas, S.W, Clark, S.J

Get full text

Covering the PASS: Development of Protocol Template Language (PTL) for Data Collection and Data Management (DM) in Post-Authorization Safety Studies (PASS) by Oberthur Johnson, L, Watts, H, Krishnan, S, Zarotsky, V, Spannheimer, A, Siebenaler, J, Gulyas, S, Clark, S

Get full text

A comprehensive review of predictive and prognostic composite factors implicated in the heterogeneity of treatment response and outcome across disease areas by Alatorre, C I, Carter, G C, Chen, C, Villarivera, C, Zarotsky, V, Cantrell, R A, Goetz, I, Paczkowski, R, Buesching, D

“…To assess and present the current body of evidence regarding composite measures associated with differential treatment response or outcome as a result of…”
Get more information

The economics of upper gastrointestinal bleeding in a US managed-care setting: a retrospective, claims-based analysis by Cryer, B L, Wilcox, C M, Henk, H J, Zlateva, G, Chen, L, Zarotsky, V

“…To assess 12-month healthcare resource utilization and costs associated with upper gastrointestinal (UGI) bleeding events. Patients hospitalized with a UGI…”
Get more information

Multiple-Dose Plasma Pharmacokinetic and Safety Study of LY450108 and LY451395 (AMPA Receptor Potentiators) and Their Concentration in Cerebrospinal Fluid in Healthy Human Subjects by Jhee, S. S., Chappell, A. S., Zarotsky, V., Moran, S. V., Rosenthal, M., Kim, E., Chalon, S., Toublanc, N., Brandt, J., Coutant, D. E., Ereshefsky, L.

“…The objective of this study was to measure the steady‐state cerebrospinal fluid (CSF) concentration of LY450108 and LY451395 (positive modulators of AMPA…”
Get full text

Pharmacokinetic(PK)/pharmacodynamic(PD) evaluation of CHF 2819.01 (novel cholinesterase inhibitor) in patients with probable Alzheimer's disease by Jhee, S. S., Fabbri, L., Zarotsky, V., Piccinno, A., Rosenthal, M., Moran, S. V., Ereshefsky, L.

“…Background To assess the plasma and CSF pharmacokinetics/pharmacodynamics of CHF 2819.01 in patients with AD. Methods An open label study evaluating 5 patients…”
Get full text

PRM19 - Development of an algorithm that differentiates among risk factors, comorbidities, and consequences of disease in peer-reviewed publications by Carman, W., Zarotsky, V.

Get full text

First clinical evaluation of ganstigmine in patients with probable Alzheimer's disease by JHEE, S. S, FABBRI, Laura, PICCINNO, A, MONICI, P, MORAN, S, ZAROTSKY, V, TAN, E. Y, FRACKIEWICZ, E. J, SHIOVITZ, T

“…The objective of this study was to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of five fixed doses of…”
Get full text

PRM38 - Building a bridge: ICD-9-CM to ICD-10-CM mapping challenges and solutions by Seare, J., Yang, J., Yu, S., Zarotsky, V.

Get full text

PIH7 - The Prevalence, Incidence, And Treatment Rates Of Hypogonadism In Men Across Geographies: A Systematic Literature Review by Huang, M.Y., Parker, G., Zarotsky, V., Carman, W., Morgentaler, A., Jones, H., Singhal, P.

Get full text

PRM15 - Please pass the new template: developing non-interventional study report writing templates aligned with guidelines by Oberthur Johnson, L., Zarotsky, V., Spannheimer, A., Gulyas, S.W., Clark, S.J.

Get full text

PIN81 - Care pathway and cost for absssi subjects with antibiotic treatment in the united states: An analysis of a real world database by Fan, W., Mao, J., Iorga, S., Zarotsky, V., LaPensee, K.T., Becker, L.

Get full text